ATE129409T1 - Neue verwendung von peptidderivat. - Google Patents

Neue verwendung von peptidderivat.

Info

Publication number
ATE129409T1
ATE129409T1 AT91121403T AT91121403T ATE129409T1 AT E129409 T1 ATE129409 T1 AT E129409T1 AT 91121403 T AT91121403 T AT 91121403T AT 91121403 T AT91121403 T AT 91121403T AT E129409 T1 ATE129409 T1 AT E129409T1
Authority
AT
Austria
Prior art keywords
hydroxy
protected
peptide derivative
chem
pharmaceutically acceptable
Prior art date
Application number
AT91121403T
Other languages
English (en)
Inventor
Takashi Fujii
Masaaki Tomoi
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE129409T1 publication Critical patent/ATE129409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91121403T 1990-12-21 1991-12-13 Neue verwendung von peptidderivat. ATE129409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP41829890 1990-12-21

Publications (1)

Publication Number Publication Date
ATE129409T1 true ATE129409T1 (de) 1995-11-15

Family

ID=18526172

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91121403T ATE129409T1 (de) 1990-12-21 1991-12-13 Neue verwendung von peptidderivat.

Country Status (9)

Country Link
US (1) US5616556A (de)
EP (1) EP0498069B1 (de)
JP (2) JPH0710778B2 (de)
KR (1) KR100235150B1 (de)
AT (1) ATE129409T1 (de)
CA (1) CA2058168A1 (de)
DE (1) DE69114117T2 (de)
DK (1) DK0498069T3 (de)
TW (2) TW222584B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
DK1246806T3 (da) 1999-11-03 2008-06-16 Amr Technology Inc Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
CN103880827B (zh) 2004-07-15 2017-01-04 阿尔巴尼分子研究公司 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
EP1904069B1 (de) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl- und heteroarylsubstituierte tetrahydrobenzazepine und verwendung damit zur wiederaufnahmeblockierung von norepinephrin, dopamin und serotonin
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
MX2011011900A (es) 2009-05-12 2012-01-20 Squibb Bristol Myers Co Formas cristalinas de (s)-7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4 -(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y usos de las misma.
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (de) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
EP2925888B1 (de) 2012-11-28 2017-10-25 Merck Sharp & Dohme Corp. Zusammensetzungen und verfahren zur behandlung von krebs
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
EP2951180B1 (de) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8-substituierte purine als hdm2-inhibitoren
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
EP3294339B1 (de) * 2015-05-15 2020-12-02 The Regents Of The University Of Michigan Verfahren und zusammensetzungen zur behandlung von arthritis
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
TWI681301B (zh) * 2018-09-07 2020-01-01 聚英企業管理顧問股份有限公司 可統計分類數量的搜尋裝置與方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8807921D0 (en) * 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Ws-9326 & its derivatives
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5093127A (en) * 1989-06-02 1992-03-03 Fujisawa Pharmaceutical Co., Ltd. Preparation of fr115224 substrate for parenteral administration
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis

Also Published As

Publication number Publication date
JPH07165601A (ja) 1995-06-27
US5616556A (en) 1997-04-01
EP0498069A3 (en) 1992-11-04
KR920012113A (ko) 1992-07-25
CA2058168A1 (en) 1992-06-22
DE69114117T2 (de) 1996-03-21
DE69114117D1 (de) 1995-11-30
TW213862B (de) 1993-10-01
TW222584B (de) 1994-04-21
EP0498069A2 (de) 1992-08-12
EP0498069B1 (de) 1995-10-25
KR100235150B1 (ko) 1999-12-15
JPH0578254A (ja) 1993-03-30
DK0498069T3 (da) 1995-12-04
JPH0710778B2 (ja) 1995-02-08

Similar Documents

Publication Publication Date Title
DE69114117D1 (de) Neue Verwendung von Peptidderivat.
DE69114614D1 (de) Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide.
GB9309324D0 (en) Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
ATE190983T1 (de) Neue tetrapeptidderivate
SE9604786D0 (sv) New compounds
ES2158537T3 (es) Derivados de acidos ciclopropilalcanoicos.
ATE165332T1 (de) Polyenderivate, diese enthaltende pharmazeutische und kosmetische zusammensetzungen und ihre verwendung
PT928788E (pt) Compostos farmaceuticamente activos
AU6601294A (en) Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
ATE81009T1 (de) N-acetyl-3-fluoroneuraminsaeure als antivirales arzneimittel.
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
IL111184A (en) Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
BR8902929A (pt) Artigo vendavel
DE69228277D1 (de) PACAP-Derivate mit c-AMP-produzierenden Eigenschaften
EP0408044A3 (en) Anti-inflammatory and/or anti-allergic composition comprising glutathione derivatives
CA2082820A1 (en) Derivatives of 6-aminooctahydroindolizinetriol
ES2057116T3 (es) Derivados de acido n-(5,6,7,8-tetrahidropirido-(2,3-d)pirimidin-6-ilalcanoil) glutamico.
DE69918098D1 (de) Neue suesstoffzusammensetzungen
AU636178B2 (en) 7 (alanylaminothiazol-iminoacetamide) substituted cephalosporin derivatives
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
DK540589A (da) Pyrrolidinderivater
EP0452809A3 (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee